New Market Research 'The Cardiovascular Market Outlook to 2011' Available Today.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c49672) has announced the addition of The Cardiovascular Market Outlook to 2011 to their offering. The Cardiovascular Market Outlook to 2011 is a new report from Business Insights providing analysis of the current and future market for cardiovascular drugs across all major indications. Forecasts are given based on new product launches, upcoming patent expiry dates expiry date expire n → date f d'expiration; (on label) → à utiliser avant ... expiry date expire n → Ablauftermin m , and ongoing clinical trials to enable you to predict changes in the dynamics of the global cardiovascular market. This report offers insight into R&D trends in the cardiovascular market, including the discontinuation dis·con·tin·u·a·tion n. A cessation; a discontinuance. Noun 1. discontinuation - the act of discontinuing or breaking off; an interruption (temporary or permanent) discontinuance of key pipeline drugs such as Pfizer's torcetrapib and atorvastatin atorvastatin /ator·va·stat·in/ (ah-tor?vah-stat´in) an antihyperlipidemic agent that acts by inhibiting cholesterol synthesis, used as the calcium salt in the treatment of hypercholesterolemia and other forms of dyslipidemia. , and the development of new drug classes including Novartis' Rasilez (aliskiren), anticipated to be the first to market direct renin renin /re·nin/ (re´nin) a proteolytic enzyme synthesized, stored, and secreted by the juxtaglomerular cells of the kidney; it plays a role in regulation of blood pressure by catalyzing the conversion of angiotensinogen to angiotensin I. inhibitor inhibitor /in·hib·i·tor/ (in-hib´i-tor) 1. any substance that interferes with a chemical reaction, growth, or other biologic activity. 2. . Use this report to identify the leading cardiovascular companies to 2011 and discover the cardiovascular blockbusters of the future. Key findings of the report... -Anti-hypertensives have been the highest selling portion of the cardiovascular market in 2005. Norvasc was the leading anti-hypertensive drug in 2005, with sales of $5bn, an increase of 3.9% from 2004. -In 2006 the patents protecting Zocor and Pravachol expired, which together with the anticipated patent expiry of Lipitor in 2010, will result in a flood of generic statins Statins A class of drugs commonly used to lower LDL cholesterol levels. Mentioned in: C-Reactive Protein onto the market, heavily impacting sales of branded drugs. -Two key anti-hypertensives are forecast to launch in 2007: Novartis' Rasilez (aliskiren) and Exforge (valsartan plus amlodipine). Exforge gained FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval in December 2006 and is predicted to generate high sales. -Pfizer's torcetrapib and atorvastatin was discontinued dis·con·tin·ue v. dis·con·tin·ued, dis·con·tin·u·ing, dis·con·tin·ues v.tr. 1. To stop doing or providing (something); end or abandon: in late 2006 due to safety concerns. The discontinuation of torcetrapib will have an impact on the other members of the CETP CETP Cholesteryl Ester Transfer Protein CETP Certified Employee Training Program CETP Common Effluent Treatment Plant CETP China Energy Technology Program CETP Centre de Recherches en Physique de l'Environment Terrestre et Planetaire (French) inhibitor pipeline drugs, in particular Roche's JTT-705. -Pfizer is the leading global cardiovascular company, with sales of nearly $20bn in 2005, representing 15.6% of the cardiovascular market. -The largest growth seen in the cardiovascular market is from Amgen at 17.4%, with sales in 2005 of $6.4bn. Key questions answered in this report -What were the key events in the global cardiovascular market in 2005-06? -What are the drivers and resistors to growth for the key players in the market? -How has the failure of key pipeline products expected to impact the global cardiovascular market? -What strategies are the leading companies implementing to maximize sales and boost market share? -When will generic competition impact the leading cardiovascular brands? -Which new product launches are forecast to gain blockbuster status? -What will the competitive landscape in hypertension, thrombosis thrombosis (thrŏmbō`sĭs), obstruction of an artery or vein by a blood clot (thrombus). Arterial thrombosis is generally more serious because the supply of oxygen and nutrition to an area of the body is halted. , dyslipidemia and arrhythmia arrhythmia (ārĭth`mēə), disturbance in the rate or rhythm of the heartbeat. Various arrhythmias can be symptoms of serious heart disorders; however, they are usually of no medical significance except in the presence of look like in 2011? Top five reasons to order your copy today -Gain up-to-date competitive intelligence across the cardiovascular area and understand the major issues affecting key pharmaceutical marketers. -Understand which cardiovascular indications have the greatest potential for growth through the 6-year forecasts in anti-hypertensive, anti-dyslipidemic, anti-thrombosis and cardiac therapy drug classes. -Assess your potential competitive position to the leading cardiovascular companies, through the report's extensive pipeline insight and profiles of upcoming launches. -Examine factors impacting pipeline drugs, such as clinical trial results, discontinued products and patient potentials. -Identify the critical success factors for your company to succeed in the cardiovascular market, through examination of winning growth strategies used by the leading players. Content Outline: The Cardiovascular Market Outlook to Executive Summary Patient potential Global cardiovascular market analysis Analysis of potential future cardiovascular blockbusters Leading players in the cardiovascular market Chapter 1 Patient potential Chapter 2 Global cardiovascular market Chapter 3 Analysis of potential future Chapter 4 Leading players in the cardiovascular market Chapter 5 Appendix IMS (1) See IP Multimedia Subsystem. (2) (Information Management System) An early IBM hierarchical DBMS for IBM mainframes. IMS was widely implemented throughout the 1970s under MVS and continues to be used under z/OS. data Index List of Figures List of Tables Companies Mentioned: -Pfizer's -Merck's -Sanofi-Aventis -Novartis -Bristol-Myers Squibb's For more information visit http://www.researchandmarkets.com/reports/c49672 Source: Business Insights |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion